Visual Outcomes of Boston Keratoprosthesis Implantation as the Primary Penetrating Corneal Procedure

被引:52
作者
Kang, Joann J. [1 ]
de la Cruz, Jose [1 ]
Cortina, Maria Soledad [1 ]
机构
[1] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA
关键词
Boston keratoprosthesis; limbal stem cell deficiency; penetrating keratoplasty; STEM-CELL TRANSPLANTATION; UNIVERSITY-OF-CALIFORNIA; TYPE-1; KERATOPROSTHESIS; KERATOLIMBAL ALLOGRAFT; SUBEPITHELIAL AMYLOIDOSIS; KERATOPLASTY;
D O I
10.1097/ICO.0b013e31823f7765
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To report the short-term visual outcomes and complications of keratoprosthesis surgery as the primary penetrating corneal procedure for patients at high risk for conventional corneal transplantation. Methods: A retrospective chart review was conducted of 21 eyes of 19 patients who underwent either Boston keratoprosthesis type I or type II as the primary penetrating corneal procedure from February 2007 to March 2011. Results: Nineteen type I (90.5%) and 2 type II (9.5%) Boston keratoprosthesis procedures were performed in 19 patients. Mean follow-up was 14.6 months (range, 6-36.3 mo). Primary indications for surgery included chemical or thermal injury, aniridia, and Stevens-Johnson syndrome. Preoperative best-corrected visual acuity (BCVA) ranged from 20/100 to light perception and was count fingers or worse in 20 eyes (95.2%). At last follow-up for all eyes, 15 eyes (71.4%) achieved BCVA >= 20/200 and 4 eyes (19%) improved to BCVA >= 20/50. No intraoperative complications occurred. Postoperative complications include retroprosthetic membrane formation (47.6%), cystoid macular edema (33.3%), elevated intraocular pressure (23.8%), glaucoma progression (14.3%), and endophthalmitis (4.8%). The initial keratoprosthesis was retained in 19 eyes (90.5%). Conclusion: The Boston keratoprosthesis, based on early follow-up, is a good alternative as a primary penetrating corneal procedure in a select group of patients with very poor prognosis for penetrating keratoplasty. Although complications can occur and require close monitoring, visual acuity significantly improved in the majority of patients.
引用
收藏
页码:1436 / 1440
页数:5
相关论文
共 25 条
[1]   The Boston Type I Keratoprosthesis Improving Outcomes and Expanding Indications [J].
Aldave, Anthony J. ;
Kamal, Khairidzan M. ;
Vo, Rosalind C. ;
Yu, Fei .
OPHTHALMOLOGY, 2009, 116 (04) :640-651
[2]   Boston Type 1 Keratoprosthesis: The University of California Davis Experience [J].
Bradley, Jay C. ;
Hernandez, Enrique Graue ;
Schwab, Ivan R. ;
Mannis, Mark J. .
CORNEA, 2009, 28 (03) :321-327
[3]   Boston Keratoprosthesis Outcomes and Complications [J].
Chew, Hall F. ;
Ayres, Brandon D. ;
Hammersmith, Kristin M. ;
Rapuano, Christopher J. ;
Laibson, Peter R. ;
Myers, Jonathan S. ;
Jin, Ya-Ping ;
Cohen, Elisabeth J. .
CORNEA, 2009, 28 (09) :989-996
[4]   Introduction to the use of the Boston keratoprosthesis [J].
Dohlman, Claes H. ;
Harissi-Dagher, Mona ;
Khan, Bilal F. ;
Sippel, Kimberly ;
Aquavella, James V. ;
Graney, John M. .
EXPERT REVIEW OF OPHTHALMOLOGY, 2006, 1 (01) :41-48
[5]  
Dohlman Claes H., 2002, CLAO Journal, V28, P72
[6]   Short-Term Visual Outcomes of Boston Type 1 Keratoprosthesis Implantation [J].
Dunlap, Karen ;
Chak, Garrick ;
Aquavella, James V. ;
Myrowitz, Elliott ;
Utine, Canan Asli ;
Akpek, Esen .
OPHTHALMOLOGY, 2010, 117 (04) :687-692
[7]   Longer-Term Vision Outcomes and Complications with the Boston Type 1 Keratoprosthesis at the University of California, Davis [J].
Greiner, Mark A. ;
Li, Jennifer Y. ;
Mannis, Mark J. .
OPHTHALMOLOGY, 2011, 118 (08) :1543-1550
[8]   Importance of nutrition to corneal grafts when used as a carrier of the Boston keratoprosthesis [J].
Harissi-Dagher, Mona ;
Khan, Bilal F. ;
Schaumberg, Debra A. ;
Dohlman, Claes H. .
CORNEA, 2007, 26 (05) :564-568
[9]   Management of aniridic keratopathy with keratolimbal allograft: A limbal stem cell transplantation technique [J].
Holland, EJ ;
Djalilian, AR ;
Schwartz, GS .
OPHTHALMOLOGY, 2003, 110 (01) :125-130
[10]   Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders [J].
Ilari, L ;
Daya, SM .
OPHTHALMOLOGY, 2002, 109 (07) :1278-1284